75 and older, any sex, with Type 2 Diabetes Treated With Insulin or Hypoglycemia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Clinical Outcome: Number of Participants With Glycemic Regimen De-prescribingPrimary· 6 months after initial primary care visit
Aggregate binary measure of diabetes medication deprescribing between baseline and 6-month follow-up. Greater de-prescribing is better.
De-prescribing defined as any combination of:
1. Discontinuation of either insulin or a sulfonylureas (SU)
2. Reduction in dose of insulin or SU,
3. Switch from a higher risk to lower risk version of insulin (e.g. from sliding scale insulin or basal-bolus insulin to twice daily basal insulin) and/or higher risk to lower risk oral medicine (e.g. switching from SU to other oral medicine less associated with hypoglycemia).
Group
Value
95% CI
Pre-Visit Conversation Aid
34
General Health Education Handout
21
Patient-Reported Outcome: Number of Participants With Self-Reported HypoglycemiaPrimary· Preceding 6 month period (asked 6 months after initial primary care visit)
Patient report of any low blood sugar episode in past 6 months that resulted in passing out or needing help from someone else
Group
Value
95% CI
Pre-Visit Conversation Aid
10
General Health Education Handout
13
Sponsor's own description
This study will evaluate the impact of academic detailing (evidence-based provider education) with or without patient pre-visit preparation (elicitation of values and preferences) on safe insulin de-prescribing among older patients with type 2 diabetes at risk for hypoglycemia. The hypothesis is that patients who are well-prepared for their primary care visit will engage in more informed discussions with their providers regarding re-evaluation of current treatment regimens. In clinically appropriate cases, these more effective discussions will result in safe de-prescribing and fewer future episodes of hypoglycemia.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Other recruiting trials for Type 2 Diabetes Treated With Insulin
Currently open trials in the same condition.
NCT07063420 — Patient Centered Multi-Agent Decision Support System (PCM-DSS) for Healthcare Providers
· NA
· recruiting
NCT05317585 — Continuous Glucose Monitor Use in Pregnancy
· NA
· recruiting
NCT06311019 — The Effects of CGM and Connected Pen in T2DM Treated With Multiple Daily Insulin Injections
· NA
· active not recruiting
Other Kaiser Permanente trials
Trials by the same sponsor.
NCT07522645 — Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Dis
· NA
· not yet recruiting
NCT07474038 — AI-Supported Cognitive Rehabilitation for Older Adults With Mild Cognitive Impairment
· NA
· enrolling by invitation
NCT07467668 — Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure
· NA
· not yet recruiting
NCT07216859 — Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)
· NA
· not yet recruiting
NCT07264062 — MetSense Pilot and Feasibility
· NA
· enrolling by invitation
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kaiser Permanente
Last refreshed: 21 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04585191.